Tag: Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. BMS is a differentiated company, led by BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. Company’smedicines are helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through its R&D organization, BMS have built a sustainable pipeline of potential therapies and partner with external innovation to broaden and accelerate its work.

First Approval of Opdivo for Treatment of Advanced Esophageal Cancer

Bristol-Myers Squibb Company announced Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved Opdivo (nivolumab) for the treatment of patients with unresectable advanced or recurrent esopha...

FDA Accepts for Priority Review its Biologics License Application for Lisocabtagene Maraleucel (liso...

Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its Biologics License Application (BLA) for lisocabtagene maraleucel (liso-cel)...

BioMotiv and Bristol-Myers Squibb Announce the Launch of Anteros Pharmaceuticals

BioMotiv, a mission-driven drug development accelerator associated with The Harrington Project for discovery and development, that advances breakthrough discoveries from research institutions into the...

FDA Granted Breakthrough Therapy Designation to BMS and Nektar

Nektar Therapeutics and Bristol-Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for investigational agent bempegaldesleukin (NKTR-2...

Bayer, BMS and Ono in Clinical Collaboration Agreement

pills
Bayer, Bristol-Myers Squibb Company and Ono Pharmaceutical Co.,Ltd. (“Ono”) announced today that the three companies have entered into a clinical collaboration agreement to evaluate the combination of...

Catalent Buys Italian Facility of BMS

Customers to have access to state-of-the-art sterile biologics fill/finish and oral solids manufacturing and packaging platforms. Bristol-Myers Squibb (BMS) and Catalent have announced that Catalent ...

Bristol-Myers Announced New R&D Team

bristol-myers squibb
Bristol-Myers Squibb has unveiled the new-look team that will lead its R&D group after the closure of its Celgene takeover. The Big Pharma is dividing the group up into early- and late-phase d...

Bristol-Myers Squibb Shareholders Approve the Acquisition of Celgene

Bristol-Myers Squibb shareholders approved the pharmaceutical giant’s $74 billion acquisition of cancer drugmaker Celgene. The deal, announced in January, was a hard sell to Bristol shareholders from ...

BMS Urges Shareholders to Vote FOR Acquisition of Celgene

Bristol-Myers Squibb Company today filed a new investor presentation with the Securities and Exchange Commission (SEC) in connection with its previously announced definitive merger agreement with Celg...

Phase 4 Results of BMS-Pfizer Trial

The Bristol-Myers Squibb-Pfizer Alliance announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis® (apixaban) versus vitamin K antagonists (VKAs) in patients with non-valvular atrial fibri...

Starboard to Vote against BMS and Celgene Merge

celgene
Doubts are mounting about whether Bristol-Myers Squibb’s $74 billion merger with Celgene will go ahead after another key investor came out against the deal. Hedge fund Starboard Value followed BMS’...

Big Pharma Answered for High Prices

U.S. senators called drug pricing practices “morally repugnant” and told drug company executives they do not want to hear them blame others for the high prices, taking an aggressive stance at a Senate...

Big Pharma to Testify in High Drug Pricing Case

While congressional scrutiny on drug pricing is nothing new, the prospect of some of the pharmaceutical industry's highest-profile CEOs testifying on the issue will make for a must-watch event. In ...

Celgene Announce Better-than-Expected Profit

Celgene Corp, which is being bought by Bristol-Myers Squibb Co, reported a better-than-expected fourth-quarter profit on Thursday, driven mainly by higher sales of psoriasis drug Otezla. Bristol-My...

New Deal of Celgene is for Blood Cancers Treatment

Celgene has struck another collaborative deal, even as the large pharmaceutical company is in the process of being folded into the operations of its new owner, Bristol-Myers Squibb. This morning, p...

EMA Approved BMS Kidney Cancer Drug

Bristol-Myers Squibb has claimed a new approval for its immuno-oncology combination of Opdivo and Yervoy, getting a green light from the European Medicines Agency (EMA) for its use in renal cell carci...